Spotlight on Camrelizumab in Advanced Squamous Lung Cancer : Another Feather in the Cap of Chinese Checkpoint Inhibitors
| Errataetall: |
CommentOn: J Thorac Oncol. 2022 Apr;17(4):544-557. - PMID 34923163 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 17(2022), 4 vom: 01. Apr., Seite 477-480 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Reguart, Noemi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
73096E137E |
|---|
| Anmerkungen: |
Date Completed 29.04.2022 Date Revised 29.04.2022 published: Print CommentOn: J Thorac Oncol. 2022 Apr;17(4):544-557. - PMID 34923163 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jtho.2022.01.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM338376224 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338376224 | ||
| 003 | DE-627 | ||
| 005 | 20231226000530.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jtho.2022.01.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1127.xml |
| 035 | |a (DE-627)NLM338376224 | ||
| 035 | |a (NLM)35307102 | ||
| 035 | |a (PII)S1556-0864(22)00027-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Reguart, Noemi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Spotlight on Camrelizumab in Advanced Squamous Lung Cancer |b Another Feather in the Cap of Chinese Checkpoint Inhibitors |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.04.2022 | ||
| 500 | |a Date Revised 29.04.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentOn: J Thorac Oncol. 2022 Apr;17(4):544-557. - PMID 34923163 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a camrelizumab |2 NLM | |
| 650 | 7 | |a 73096E137E |2 NLM | |
| 650 | 7 | |a Carboplatin |2 NLM | |
| 650 | 7 | |a BG3F62OND5 |2 NLM | |
| 650 | 7 | |a Paclitaxel |2 NLM | |
| 650 | 7 | |a P88XT4IS4D |2 NLM | |
| 700 | 1 | |a Reyes, Roxana |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer |d 2006 |g 17(2022), 4 vom: 01. Apr., Seite 477-480 |w (DE-627)NLM169435504 |x 1556-1380 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2022 |g number:4 |g day:01 |g month:04 |g pages:477-480 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jtho.2022.01.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2022 |e 4 |b 01 |c 04 |h 477-480 | ||